A Wary Eye on Bausch & Lomb

Bausch & Lomb (BOL) has become the latest in a string of health-care companies to have one of its products potentially linked to a medical scare. The Rochester (N.Y.)-based outfit's stock plummeted as much as 21% Apr. 11, amid a surge of downgrades by investment analysts, on the news that 109 patients in 17 states developed a rare and dangerous fungal eye infection in recent months.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.